U.S. prescription drug spending shot up 13.1% last year, according to a new report from Express Scripts. And the vocal price critic says it knows just who's to blame.
As the U.S. government and payers counter sky-high drug prices, a California lawmaker is proposing a new measure that would require drug companies for the first time to reveal information on how they price the industry's most expensive meds.
SINGAPORE-- A change in leadership at the China Drug and Food Administration was announced on the Communist Party website last week: Bi Jingquan, who has more than 20 years of experience in pricing and management, will take over from Zhang Yong as CFDA minister.
SINGAPORE-- More than two years in the making, Pakistan's proposed new drug-pricing policy still hasn't won over drugmakers. The country's health ministry proffered a draft that would peg prices to those in India and Bangladesh, with generic prices at 30% less, on average, than the brand price in those neighboring countries.
A California cost-effectiveness panel is prepared to say this about Gilead Sciences' brand-new combination treatment for hepatitis C: It's cost-effective, even at an eye-popping price. But--and this is a big but--the state can't afford to pay it.
A time-honored technique for boosting drug sales is simple: Raise prices. Lately, plenty of drugmakers pressed by patent-cliff losses have done just that. But some notable price hikes on diabetes drugs may be backfiring with payers. With diabetes costs taking double-digit increases--and expensive newer meds launching--insurers are tightening restrictions on drug use.
Add a new set of pricing foes for Gilead Sciences). A U.S. Senate committee has joined the forces arrayed against the company's breakthrough hepatitis C drug Sovaldi and its $84,000 price tag.
Rep. Henry Waxman and several Democratic colleagues in Congress wrote Gilead CEO John Martin an excoriating letter on Friday, demanding to know why Gilead Sciences' hepatitis C wonder drug Sovaldi costs $84,000--and whether Gilead is doing anything to make sure that poor patients get access to it.
The New York Times recently found out that different patients treated in a recent food-poisoning event paid prices that ranged over hundreds of dollars for basic IV saline solution. More surprising is that the Medicare-approved rate for a liter of saline that can end up at $90 starts at $1.07 a liter.
The U.K. government is the latest to start looking to tamp down prices on already-approved drugs as it tries to take control of what it sees as runaway healthcare costs.